236 related articles for article (PubMed ID: 29660665)
1. Investigation of anti-Hepatitis C virus, sofosbuvir and daclatasvir, in pure form, human plasma and human urine using micellar monolithic HPLC-UV method and application to pharmacokinetic study.
Zidan DW; Hassan WS; Elmasry MS; Shalaby AA
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jun; 1086():73-81. PubMed ID: 29660665
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a versatile HPLC-DAD method for simultaneous determination of the antiviral drugs daclatasvir, ledipasvir, sofosbuvir and ribavirin in presence of seven potential impurities. Application to assay of dosage forms and dissolution studies.
Baker MM; Hammad SF; Belal TS
Drug Dev Ind Pharm; 2019 Jul; 45(7):1111-1119. PubMed ID: 30929537
[TBL] [Abstract][Full Text] [Related]
3. Efficient HPTLC-dual wavelength spectrodensitometric method for simultaneous determination of sofosbuvir and daclatasvir: Biological and pharmaceutical analysis.
Abo-Zeid MN; El-Gizawy SM; Atia NN; El-Shaboury SR
J Pharm Biomed Anal; 2018 Jul; 156():358-365. PubMed ID: 29753282
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits.
Atia NN; El-Shaboury SR; El-Gizawy SM; Abo-Zeid MN
J Pharm Biomed Anal; 2018 Sep; 158():88-93. PubMed ID: 29864695
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of LC-MS/MS method for simultaneous determination of sofosbuvir and daclatasvir in human Plasma: Application to pharmacokinetic study.
Abdallah OM; Abdel-Megied AM; Gouda AS
Biomed Chromatogr; 2018 Jun; 32(6):e4186. PubMed ID: 29314090
[TBL] [Abstract][Full Text] [Related]
6. Optimization of a sensitive and robust strategy for micellar electrokinetic chromatographic analysis of sofosbuvir in combination with its co-formulated hepatitis C antiviral drugs.
Rageh AH; Abdel-Aal FAM; Pyell U
J Chromatogr A; 2020 Apr; 1616():460795. PubMed ID: 31918849
[TBL] [Abstract][Full Text] [Related]
7. Micellar high performance liquid chromatographic method for separation and validation of two anti-hepatitis C- virus drugs in pure form, human plasma and human urine.
Hassan WS; Elmasry MS; Shalaby A; El-Sayed HM; Zidan DW
Ann Pharm Fr; 2020 May; 78(3):217-229. PubMed ID: 32253022
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of six sequential spectrophotometric methods for quantification and separation of ribavirin, sofosbuvir and daclatasvir: An application on Laboratory prepared mixture, pharmaceutical preparations, spiked human urine, spiked human plasma, and dissolution test.
Hassan WS; Elmasry MS; Elsayed HM; Zidan DW
Spectrochim Acta A Mol Biomol Spectrosc; 2018 Sep; 202():159-173. PubMed ID: 29783148
[TBL] [Abstract][Full Text] [Related]
9. UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients.
Notari S; Tempestilli M; Fabbri G; Libertone R; Antinori A; Ammassari A; Agrati C
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1073():183-190. PubMed ID: 29276983
[TBL] [Abstract][Full Text] [Related]
10. Validated RP-HPLC Method for Simultaneous Determination of Ribavirin, Sofosbuvir and Daclatasvir in Human Plasma: A Treatment Protocol Administered to HCV Patients in Egypt.
Youssef AA; Magdy N; Hussein LA; El-Kosasy AM
J Chromatogr Sci; 2019 Aug; 57(7):636-643. PubMed ID: 31063182
[TBL] [Abstract][Full Text] [Related]
11. Chemometrically Assisted Development of Ultra-High-Performance Liquid Chromatography Method for the Simultaneous Quantification of Sofosbuvir, Daclatasvir and Ledipasvir in Pharmaceutical Dosage Forms.
Labidi A; El Atrache LL
J Chromatogr Sci; 2020 Jan; 57(10):910-919. PubMed ID: 31644804
[TBL] [Abstract][Full Text] [Related]
12. HPLC-UV and TLC-Densitometry Methods for Simultaneous Determination of Sofosbuvir and Daclatasvir: Application to Darvoni® Tablet.
Fayed AS; Hegazy MA; Kamel EB; Eissa MS
J Chromatogr Sci; 2022 Jul; 60(6):606-612. PubMed ID: 34355234
[TBL] [Abstract][Full Text] [Related]
13. Green analytical chromatographic assay method for quantitation of cyclobenzaprine in tablets, spiked human urine and in-vitro dissolution test.
Walash MI; El Abass Mohamed SA
Ann Pharm Fr; 2019 Sep; 77(5):418-425. PubMed ID: 31296331
[TBL] [Abstract][Full Text] [Related]
14. Two validated spectrofluorimeteric and high performance liquid chromatography (HPLC) methods with fluorescence detection for the analysis of a new anti-hepatitis C drug, daclatasvir hydrochloride, in raw material or tablet form and in biological fluids.
Aboshabana R; Shalan S; Eid M; El-Enany N
Luminescence; 2018 Dec; 33(8):1333-1345. PubMed ID: 30350338
[TBL] [Abstract][Full Text] [Related]
15. Micellar spectrofluorimetric protocol for the innovative determination of HCV antiviral (daclatasvir) with enhanced sensitivity: Application to human plasma and stability study.
Abdel-Lateef MA; Omar MA; Ali R; Derayea SM
Spectrochim Acta A Mol Biomol Spectrosc; 2019 Jan; 206():57-64. PubMed ID: 30081268
[TBL] [Abstract][Full Text] [Related]
16. Validated spectrophotometric and chromatographic methods for analysis of the recently approved hepatitis C antiviral combination ledipasvir and sofosbuvir.
Baker MM; El-Kafrawy DS; Mahrous MS; Belal TS
Ann Pharm Fr; 2018 Jan; 76(1):16-31. PubMed ID: 28842163
[TBL] [Abstract][Full Text] [Related]
17. RP-HPLC method development and validation for quantification of daclatasvir dihydrochloride and its application to pharmaceutical dosage form.
Hussain Shah SS; Nasiri MI; Sarwar H; Ali A; S Naqvi SB; Anwer S; Kashif M
Pak J Pharm Sci; 2021 May; 34(3):951-956. PubMed ID: 34602418
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a stability-Indicating RP-HPLC method for simultaneous estimation of sofosbuvir and velpatasvir in fixed dose combination tablets and plasma.
Mehmood Y; Khan IU; Shahzad Y; Khalid SH; Irfan M; Asghar S; Yousaf AM; Hussain T; Khalid I
Pak J Pharm Sci; 2019 Jul; 32(4(Supplementary)):1835-1842. PubMed ID: 31680080
[TBL] [Abstract][Full Text] [Related]
19. Validated stability-indicating HPLC-DAD method for determination of the recently approved hepatitis C antiviral agent daclatasvir.
Baker MM; El-Kafrawy DS; Mahrous MS; Belal TS
Ann Pharm Fr; 2017 May; 75(3):176-184. PubMed ID: 28187879
[TBL] [Abstract][Full Text] [Related]
20. Improved spectral resolution for the rapid simultaneous spectrophotometric determination of sofosbuvir and daclatasvir as anti hepatitis C virus drugs in pharmaceutical formulation and biological fluid using continuous wavelet and derivative transform.
Keyvan K; Sohrabi MR; Motiee F
Spectrochim Acta A Mol Biomol Spectrosc; 2021 Apr; 251():119429. PubMed ID: 33477087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
